Xalieve(TM) Gains Momentum As Calabar AB Launches A Phase II Repeated Dose Study In Dry Mouth Patients
Oct 3rd 2008Drug InformationClinical Trials
Calabar AB announced that their Phase II repeated dose study in xerostomia (”dry mouth”) patients has been initiated. Specifically, the drug will be studied in 45 dry mouth patients between the ages of 20 to 75. The objective of the study is to select a dose for evaluation in a succeeding Phase III efficacy study. Xalieve(TM) is a gel containing the cholinesterase inhibitor physostigmine.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
